Project Grant R01CA306089
Award Date 8/18/25
Completion Date 7/31/30
Dollars Obligated $697K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
- This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $1,164,814 to O2M Technologies LLC to develop an advanced imaging technology using pulse electron paramagnetic resonance (PEPR) for precise measurement of partial oxygen pressure (pO2) in cancer and other medical applications. The key products and services to be delivered include: Establishing the hardware to implement variable flip-angle sequences with...
- This $419,133 federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of the "AscitesPredict" biosensor technology at the Massachusetts Institute of Technology (MIT). The goal is to overcome challenges in predicting therapeutic sensitivities for difficult-to-treat cancers like gastroesophageal and ovarian cancer, by leveraging patient ascites (fluid buildup) as a readily accessible and...
- The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...
- The federal Project Grant award of $306,872 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a new "Multi-Camera Array Scanner" (MCAS) imaging system by Ramona Optics Inc. The MCAS is designed to rapidly digitize and automatically analyze 3D fine-needle aspiration cytology slides, which are a critical first step in the cancer diagnosis pipeline. This technology aims to enable real-time assessment of specimen adequacy and provide...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Beken Bio, Inc. aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancer by assaying relevant biomarkers on circulating extracellular vesicles in patient plasma. The project will utilize a novel technology to identify key proteins in extracellular vesicles from various ovarian cancer subtypes and employ a machine...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $386,700 Project Grant to the Regents of the University of Minnesota to develop and validate targeted mass spectrometry assays for the diagnosis of serous ovarian cancer. The project will leverage a cohort of 1,300 serum samples from a diverse group of women to enable the differentiation of serous ovarian cancer patients from healthy individuals based on the abundance of diagnostic serum protein...
- The National Cancer Institute (NCI) awarded a $1,296,385 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Biotex, Inc. in Houston, TX. This direct-to-Phase II SBIR grant will accelerate the development and commercialization of a novel, non-invasive wearable device called the OncoMagnetic Device (OMTX) that uses spinning oscillating magnetic fields to treat brain cancers, including the aggressive glioblastoma (GBM). The goal is to provide a less toxic...
- The $631,621 Project Grant awarded by the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop an integrated top-down proteomics and phosphoproteomics platform to generate personalized intact proteome maps from patient-derived ovarian cancer spheroids. This platform will characterize disease states and identify markers of chemoresistance, which is critical for improving treatment of the deadliest gynecological malignancy. The project,...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...